EUVIMEDOpdag EUVIMED
EUVIMED · CrossrefJournal

ESMO Open

ISSN 2059-7029 · Elsevier BV

Latest articles

  1. Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial

    S.L. Sammons, A.E.D. Van Swearingen, N.A. Bagegni, L.A. Huppert, S.-H. Jung, G. Broadwater, K. Strickland, S. Beyer, A. Conlin, A. Morikawa, R.K. Murthy, N.U. Lin, C.K. Anders, Allison Lipps, Maura Buckley, Ashley Hughes, Jamie Douthitt, Brian Kostoff, Lisa Wood, Stephanie Masheck

    Published: 2026-12DOI: 10.1016/j.esmoop.2026.108641

  2. Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial

    A.S. Clark, C. Omene, C. Yau, A.M. Wallace, E. Stringer-Reasor, A.J. Chien, C. Isaacs, H.S. Han, K.S. Albain, J.C. Boughey, R. Nanda, H. Beckwith, Z. Mitri, E.D. Ellis, A.D. Elias, J.E. Lang, R. Shatsky, M. Howard-McNatt, T. Helsten, S. Blair, S. Woodard, C. Parker, M. Melisko, E.P. Crane, A.L. Asare, L. Brown-Swigart, G.L. Hirst, J.B. Matthews, A.L. Delson, J. Perlmutter, D. Yee, A.M. DeMichele, H.S. Rugo, N.M. Hylton, W.F. Symmans, L.J. van ‘t Veer, D.A. Berry, L.J. Esserman

    Published: 2026-12DOI: 10.1016/j.esmoop.2026.108643

  3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer

    H. Hayashi, A. Zer, H. Kenmotsu, M. Tachihara, J. Cui, N. Sutandyo, N. Lokeshwar, G.-W. Lee, P.-J. Voon, K. Samala, M.-K. Ang, C.-H. Chiu, V. Sriuranpong, T. Reungwetwattana, B.-C. Liao, R.A. Soo, G.E.I. Ladrera, A. Alip, H.R. Kim, M. Basade, C.M. Rumende, J. Wang, S. Popat, E. Lim, Y. Tsutani, Y. Matsuo, H. Minami, N. Leighl

    Published: 2026-11DOI: 10.1016/j.esmoop.2026.108533

  4. Patterns of central nervous system and leptomeningeal involvement in advanced breast cancer with invasive lobular histology: a large multicenter study with a focus on estrogen receptor-positive/HER2-negative disease

    F. Miglietta, C. Vernieri, T. Giarratano, G. Griguolo, M. Bottosso, A. Vingiani, F. Piacentini, M. Cacciatore, A. Botticelli, G. Fotia, P. Napolitano, G. Landa, G.M. Vernaci, E. Di Liso, L. Casadei, D. Palleschi, G. Pruneri, A.P. Dei Tos, V. Guarneri, M.V. Dieci

    Published: 2026-11DOI: 10.1016/j.esmoop.2026.108550

  5. Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project

    A. Arenas, C. Saura, M. Alva-Bianchi, J. de Nicolás-Hernández, M. Gion, J.M. Cejalvo, E. Llabrés, J. Cortés, A. Falcón, S. Pernas, A. López de Sa, M. Vidal, C. Hinojo, T. Curiel, J. Cruz, V. Martínez, B. Cantos, M.J. Echarri, I. Gallegos, C. Bueno, A.M. Vargas, S. Escrivá-de-Romaní, B. Fullana, M.A. Cobos, L. Joval-Ramentol, P. Ortiz-Heras, T. Pascual, C. Valdivia, G. Villacampa, E. Ciruelos, C. Rodriguez-Antona, R. Sánchez-Bayona

    Published: 2026-11DOI: 10.1016/j.esmoop.2026.108607

  6. Prognostic value of PD-L1 expression and association with HRD in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1/ENGOT-ov25 trial (GINECO)

    G. Bataillon, S. Cyrille, A. Salvioni, A. Trecourt, C. Jeanne, C. Genestie, I. Ray-Coquard, E. Pujade-Lauraine, R. De Cecio, U. Canzler, C. Zamagni, P. Harter, F. Selle, P. Pautier, R. Márquez Vázquez, O. Tome, B. You, M. Ayyoub, M. Carton, N. Weber, P.-A. Just, I. Treilleux, A. Martinez, A. Vincent-Salomon

    Published: 2026-11DOI: 10.1016/j.esmoop.2026.108611

  7. Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study

    S. Kobayashi, T. Takamoto, A. Shiomi, A. Takahashi, M. Shiozawa, H. Taniguchi, Y. Nishizawa, D. Nobuoka, S. Yasuta, T. Kato, K. Ando, A. Taketomi, Y. Takahashi, S. Natsume, T. Kojima, T. Nakamura, R. Mitani, M. Wakabayashi, T. Yoshino, Y. Nakamura

    Published: 2026-11DOI: 10.1016/j.esmoop.2026.108622

Volumes

2026 · 2,0822025 · 1,6332024 · 1,4262023 · 1,0832022 · 3482021 · 2952020 · 2172019 · 1142018 · 1,1532017 · 992016 · 102

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.